Table 1. Summary of the experimental parameters of the studies analyzed.

	Monkey species	Number of monkeys (ctl/vac)	Challenge virus	Challenge route	Challenge frequency	Challenge dose	Maximum number of challenges	Treatment	Efficacy¶
Ellenberger06v	pigtailed macaques	14/16	SHIV-SF162P3	rectal	weekly	virus particles	up to 26	DNA/MVA vaccine	64%
Wilson06jv	rhesus macaques	8/8	SIVmac239	rectal	weekly	†	8	DNA/Ad5 vaccine	NS0
Wilson09jv	rhesus macaques	8/8	SIVsmE660	rectal	3 weeks	virus particles	5	DNA/Ad5 vaccine	NS0
GarciaLerma08pm	rhesus macaques	18/24	SHIV-SF162P3	rectal	weekly	virus particles	14	FTC/TDF pre-exposure prophylaxis	74–87%
Hansen09nm	rhesus macaques	15/12	SIVmac239	rectal	weekly	FFU‡	8	RhCMV/SIV vaccine	ND*
Hansen11n	rhesus macaques	28/33	SIVmac239	rectal	weekly	FFU‡	25	RhCMV/SIV & DNA/Ad5 vaccines	NS0
Letvin11stm	rhesus macaques	20/20	SIVmac251	rectal	weekly	1	12	DNA/Ad5 vaccine	NS0
Letvin11stm	rhesus macaques	43/43	SIVsmE660	rectal	weekly	1	12	DNA/Ad5 vaccine	50%

^†“Tissue culture infectious dose 50”;

^‡“focus forming units”;

^Δ“animal infectious dose at which 50% become infected”;

^¶the efficacy of the intervention on susceptibility to challenge;

^*not done;

⁰not significantly different from 0%.